



Roadmapping the Transition to Digital Medicines Information



Roundtable Report Feb 2022

Contents

SMP overview

• Roundtable

Structure

Background

<u>Innovations</u>

<u>Takeaways</u>

Feedback

- Next steps
- References
- Contact us

Page 3-6

<u>Page 7-24</u>

Page 8-9

Page 10-14

Page 15-18

Page 19-23

Page 24

Page 25-26

Page 27

Page 28

4.5 Trillion medicines made every year ¹

But:

- Billions of effective medicines discarded unused ^{2,3}
- Billions of medicines lost due to packaging or delivery failures ^{4,5}
- Huge environmental cost 25% healthcare CO2e in medicines ²⁻⁷
- Huge financial cost \$billions wasted every year ²⁻⁷
- Two billion people do not have access to basic medicines

Solutions require collective stewardship, commitment, and action.

Sustainable Medicines Partnership

A multi-stakeholder global partnership executing a programme to build, test & scale sustainable medicines frameworks and solutions.




Concept 2020
Programme design 2021
Programme delivery 2022-2025
Solutions scaled 2026-2030

SMP Programme

Four year programme to deliver science-based, scalable solutions through integrated Projects.

SMP Projects:

- Target 6 pillars of sustainable medicines.
- Deliver data-driven solutions.
- Deliver sector-wide frameworks.
- Deliver standards and metrics.
- Deliver implementation toolkits.




Pillars of Sustainable Medicines

P1 Measurable impacts
Design and
implement metrics

P6 Sustainable packaging
Circular solutions to reduce single-use packaging

P5 Every dose used
Reallocate unused medicines



End-to-end visibility

Dynamic tracking through supply chain

P2

Better shelf life

Incentivise shelf life extension

P3

Digital by default

Patient-centred medicines information

P4





SMP Roundtable

Roadmapping the transition to digital medicines information



18th November 2021

Roundtable structure

Sector-wide participation

43 participants across whole community


Innovation presentations

Cutting-edge content

Small & large group discussion

Structured so every voice heard

Roundtable participants



Roundtable Poll: individuals identified themselves as part of one or more of the SMP stakeholder groups.



Roadmapping the transition to digital medicines information

Background

Medicines Information - current landscape

Complex with high regional variability
Mixed professional, patient, and product information

Information for Professionals



Digital in most territories
US is an exception
~30+ pages

Information for Patients



Printed in most territories
Not patient-centred
~4-7 pages (normal font)

Why Change - Patients

Research shows current leaflets are: 9-13

- Hard to read: small font, complex language
- Hard to search: for relevant content
- Hard to update: impacting patient safety
- Hard to adapt: to different platforms / patients
- Hard to access: content lost, if leaflet lost



Medicines information must better serve patient needs

Why Change - Planet



>100 Billion paper leaflets produced / year.

- Require huge quantities of trees, water, energy
- 20% are never packed, for multiple reasons
- Increase size, weight, and storage requirements
- Increase transport requirements
- Generate ~500,000 tonnes CO2e / year

100B leaflets needs: 14



9 million trees



H20 = fill Sydney harbour 4 times



Energy = fuel 50,000 homes for a year

Paper is a valuable resource that should never be wasted

Why Change - Business

Paper leaflets impact medicines manufacture:

- 10% machinery downtime due to leaflet issues
- Add ~6 months to lead time
- Market specificity limits supply flexibility
- Repetitive bulk manual handling for employees
- Leaflet changes add delays and waste



Paper leaflets cause delays and waste of medicines



Roadmapping the transition to digital medicines information

Innovations

Innovations - Policy

The Therapeutic Products Branch (TPB) finalized guidance on e-labelling of therapeutic products (TPs) in Singapore has been published and will take effect from 30 April 2021. As part of HSA's calibrated approach, only prescription-only medicines will be eligible for e-labelling.

E-PIL
Belgium & Luxembourg
Pioneer Pilot Project

BALTIC REGULATORY AGENCIES ANNOUNCE THE EPIL PROJECT FOR HOSPITAL USE MEDICINES

Notice: Product Monograph Implementation Plans

May 12, 2020

Our Reference No: 19-123473-315

Electronic product information for human medicines in the EU: key principles

A joint EMA-HMA-EC collaboration

Pharmaceuticals and Medical Devices Safety Information

No. 381 March 2021

Ministry of Health, Labour and Welfare & Pharmaceutical Safety and Environmental Health Bureau,
Labour and Welfare, Japan

Many health systems are trialling digital medicines information¹⁵

Innovations - Content















Digital content (text, audio, video) is increasingly available 16



Innovations - Access






myHealthbox APIs



First Databank's Authoritative Drug Information Helps Answer Customer Questions on Amazon Alexa

Specialized answers about medication information were created specifically for voice-enabled service







Many ways to access digital content are becoming available 17



Roadmapping the transition to digital medicines information

Roundtable Takeaways

Top 3 takeaways

Patients First	Patient need and safety should be the primary determinant of information content and access.	
Implementation by Integration	Data from existing research, pilots, real world evidence should be integrated to deliver change.	
Digital by 2025	Digital medicines information should be the default mode of communication by 2025.	

Patients First

Medicines information:

- **Simpler content**: to increase understanding & adherence
- Multimedia formats: to increase accessibility
- Multilingual: to increase accessibility
- Dynamic & always up-to-date: to increase safety
- **Structured & searchable**: to improve user experience
- Linked as standard: to other formats and information




Patient need & safety should determine content and access

Additional information should be readily available as required

Implementation by Integration

Broad consensus on digital transition principles.

- Manufacturers: many product-specific pilots
- **Health professionals**: many supportive research studies
- Patients: studies all show need for improvement
- **Health systems**: several already on digital roadmap
- Policymakers: many recommend digital transition




Integration of the abundance of data & research can provide an evidence-based digital implementation roadmap

Digital by 2025

Digital information:

- is flexible, accessible, dynamic, inter-operable
- can be accessed in different ways and formats
- is already used by most professionals and citizens
- requires much less natural resource to produce
- will reduce stock loss and medicines waste



Roundtable Poll: 67% believed digital medicines information should be the default by 2025, 100% by 2030.

Digital medicines information should be the primary format by 2025

Alternatives should be readily available as required

Good background on the scale of the problem and the issues faced in packaging. Useful to hear different viewpoints and the obstacles that need to be overcome.

Great structure and pace. Very much liked the focus on not presupposing the problem space, but drawing that out from the groups.

Roundtable feedback

People with different background and perspectives working towards the same goal.

Helpful to make connections across wider groups.

Multi-stakeholder and experienced panel.
Useful sharing of initiatives from other markets.

Great small group discussions. All perspectives honored and included.

Efficient way to gather information - learnt a lot.

100% of survey respondents found the Roundtable useful



Roadmapping the transition to digital medicines information

Next Steps

SMP Project - Digitising medicines information

'One-Page' essential content	Patient-centred, interoperable, standardised, core content. ¹⁸	
Prototype 'digital-first'	Hospital medicines: leaflets are not given to hospital patients, digital can be the default.	
Implementation frameworks	Integrate research and real world data to build digital transition roadmaps.	

References

- 1. Global Medicines Use in 2020
- 2. Expired Medication: societal, regulatory and ethical aspects of a wasted opportunity
- 3. <u>Evaluation of the scale, causes and costs of waste medicines</u>
- 4. Failures in temperature-controlled logistics cost biopharma industry billions
- 5. <u>Ensuring a safe and robust supply of pharma materials</u>
- 6. A carbon footprint assessment of the NHS
- 7. The role of material efficiency in environmental stewardship
- 8. Access to Medicine Foundation Worldwide 5 billion people have access to medicine
- 9. From print to screen: regulatory considerations to adopting innovative approaches to patient information
- 10. Provision and need for medicine information in Asia and Africa
- 11. Readability of medicinal package leaflets: a systematic review
- 12. Advancing best practices for prescription drug labeling
- 13. <u>Protecting seniors from medication labelling mistakes</u>
- 14. Extrapolated from AstraZeneca internal data
- 15. Policy Innovations each image is a hyperlink to reference
- 16. Content Innovations each image is a hyperlink to reference
- 17. Access Innovations each image is a hyperlink to reference
- 18. The science of communicating medication information to consumers



Contact us



If you would like to be involved email: info@yewmaker.com
Read more about YewMaker and the SMP: https://www.yewmaker.com/

Follow us:

Twitter <u>@YewMaker</u> LinkedIn YewMaker We thank all participants for their energetic and constructive engagement

Cite as: Rahman and Mahamdallie (2022, April 8). Digitising Medicines Information Roundtable Report 2022. Retrieved from osf.io/82cfr

https://doi.org/10.17605/OSF.IO/82CFR



Content is licensed under a Creative Commons Attribution 4.0 International license (<u>CC BY</u>), by YewMaker.